These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10830407)

  • 21. Prospective value-based assessment of new health care technologies and practices.
    Girod CS; Axene DV
    Manag Care; 2000 Aug; 9(8):38-40, 43-7. PubMed ID: 11186514
    [No Abstract]   [Full Text] [Related]  

  • 22. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of medical methods--can we rely on cost-benefit-analysis?].
    Kristiansen IS; Stavem K; Linnestad K; Pedersen KM
    Tidsskr Nor Laegeforen; 2003 Mar; 123(5):657-60. PubMed ID: 12683199
    [No Abstract]   [Full Text] [Related]  

  • 24. Medical technology's impacts and costs.
    Christian J; Weissberg J
    Health Aff (Millwood); 2002; 21(1):276-7. PubMed ID: 11900092
    [No Abstract]   [Full Text] [Related]  

  • 25. [JSN treatment guideline for Parkinson's disease: its editorial policy and problems to be addressed].
    Takahashi R
    Rinsho Shinkeigaku; 2013; 53(11):1343-5. PubMed ID: 24291982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evidence in Parkinson's disease: a review.
    Lindgren P
    Eur J Health Econ; 2004 Oct; 5 Suppl 1():S63-6. PubMed ID: 15754076
    [No Abstract]   [Full Text] [Related]  

  • 27. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ICER's Revised Value Assessment Framework for 2017-2019: A Critique.
    Neumann PJ; Cohen JT
    Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].
    Gekht AB; Belousov IuB; Chikina ES; Serkin GV; Belousov DIu; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(10):26-33. PubMed ID: 15553375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methodologic considerations in planning clinical trials of cost-effectiveness of magnetic resonance imaging ... with a commentary on Guyatt and Drummond.
    Weinstein MC
    Int J Technol Assess Health Care; 1985; 1(3):567-81. PubMed ID: 10311550
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NICE and new: appraising innovation.
    Ferner RE; Hughes DA; Aronson JK
    BMJ; 2010 Jan; 340():b5493. PubMed ID: 20051468
    [No Abstract]   [Full Text] [Related]  

  • 33. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs of illness and care in Parkinson's disease.
    Korczyn AD
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):151-2. PubMed ID: 21109406
    [No Abstract]   [Full Text] [Related]  

  • 36. Relative effectiveness assessment of listed drugs (REAL): a new method for an early comparison of the effectiveness of approved health technologies.
    Falissard B; Izard V; Xerri B; Bouvenot G; Meyer F; Degos L
    Int J Technol Assess Health Care; 2010 Jan; 26(1):124-30. PubMed ID: 20059790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and economic analysis of spa therapy in Parkinson's disease.
    Brefel-Courbon C; Desboeuf K; Thalamas C; Galitzky M; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 2003 May; 18(5):578-84. PubMed ID: 12722173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entacapone: adjunctive use in patients with advanced Parkinson's disease.
    McAuley L
    Issues Emerg Health Technol; 2000 Dec; (12):1-7. PubMed ID: 11902220
    [No Abstract]   [Full Text] [Related]  

  • 39. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.